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ted equally to thisAbstract The protein binding of non-steroidal anti-inﬂammatory drugs ﬂurbiprofen, ketoprofen
and etodolac with human serum albumin (HSA) was investigated using indirect chiral high
performance liquid chromatography (HPLC) and ultraﬁltration techniques. S-(–)-1-(1-naphthyl)-
ethylamine (S-NEA) was utilized as chiral derivatization reagent and pre-column derivatization
RP-HPLC method was established for the separation and assay of the three pairs of enantiomer.
The method had good linear relationship over the investigated concentration range without
interference. The average extraction efﬁciency was higher than 85% in different systems, and the
intra-day and inter-day precisions were less than 15%. In serum albumin, the protein binding of
etodolac enantiomers showed signiﬁcant stereoselectivity that the afﬁnity of S-enantiomer was
stronger than R-enantiomer, and the stereoselectivity ratio reached 6.06; Flurbiprofen had only
weak stereoselectivity in HSA, and ketoprofen had no stereoselectivity at all. Scatchard curves
showed that all the three chiral drugs had two types of binding sites in HSA.
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work.1. Introduction
Non-steroidal anti-inﬂammatory drugs (NSAID) are a class
of drugs with the main effects of anti-inﬂammatory, plus
antipyretic, analgesic and anti-rheumatism effect. The com-
mon mechanisms of NSAID are inhibiting cyclooxygenase or
5-lipoxidase and reducing the biosynthesis of prostaglandin
(PG) to achieve the anti-inﬂammatory effect. The chemical
structure types of NSAID are various, most of which are
chiral drugs. Except a few drugs such as naproxen, most chiral
NSAID used in clinical are racemes. However, even in the
early study of chiral NSAID, it had been found that the chiral
NSAID enantiomers differed in pharmacodynamics [1,2], such
Analysis of chiral drug binding with HSA 185as 2-aryl-propionic acid (2-APA) drugs, of which it was the
S¼enantiomer that inhibited the cyclooxygenase. The stereo-
selectivity of NSAID in the drug metabolism is observed
mainly in the chiral inversion, glucuronidation and oxidation
[3–5]. Most of the 2-APA NSAID mainly undergo the one-
way conversion in in vivo, which is from R- to S-enantiomer.
In recent years, it has been found that some 2-APA drugs
demonstrate two-way choice in some species [6].
Some reports have shown that the protein binding of chiral
NSAID has stereoselectivity [7–9]. For ibuprofen, it is mainly the
R-enantiomer that binds with human serum albumin (HSA)
concentration-dependently, and the two enantiomers can be
mutually replaced. For carprofen, the R-enantiomer is apt to
bind with HSA, whereas fenoprofen almost has no stereoselec-
tivity. As NSAID could interact with plasma protein extensively
and the low hepatic uptake rate, small changes in drug protein
binding rate as well as differences of protein binding between the
enantiomers could signiﬁcantly affect the in vivo disposition
process of enantiomers of chiral drug [10]. Therefore, for these
chiral drugs with high protein binding rate, respective determina-
tion of the enantiomers’ protein binding rate as well as the
studies of interaction between enantiomers on the level of the
protein binding are necessary.
In this work, we investigated the protein binding of acidic
chiral NSAID ﬂurbiprofen, ketoprofen and etodolac with
HSA. S-(–)-1-(1-naphthyl)-ethylamine (S-NEA) was utilized
as chiral derivatization reagent and pre-column derivatization
RP-HPLC method was developed for the separation and
quantiﬁcation of the three chiral drugs. Different derivatiza-
tion conditions were investigated to obtain an optimum
separation method. This work established a foundation for
the study of their stereoselective protein binding.
2. Experimental
2.1. Apparatus and reagents
HPLC was performed on an Agilent 1100 system consisting of
G1311A pump, Aglient Zorbax C18 (250 mm 4.6 mm, 5 mm)
column, G1315A (DAD) UV detector, manual injector and
Chem-Stations software (Agilent, USA). Eppendorf refrigerate
centrifuge (Eppendorf, Germany). Microcon centrifugal system
(Millipore, USA). Electrothermal constant temperature oscillation
ﬂume (Medical Constant Temperature Corp., Shanghai, China).
Ketoprofen and ﬂurbiprofen were provided by Zhejiang
Jiuzhou Pharmaceutical Co.,Ltd., while Etodolac was kindly
provided by Ningbo Medical Science and Technology Research
Co.,Ltd. (S)-(–)-a-(1-Naphthyl) ethylamine (S-NEA), 1-hydro-
xybenzotriazole (HOBT) and 1-(3-Dimethylamine propyl)-3-
ethyl-carbimide (EDC) were purchased from Sigma-Aldrich.
Methanol and acetonitrile are of chromatographic grade. Water
used is redistilled water. All the other reagents used were of
analytical grade unless otherwise indicated.
2.2. Methods
2.2.1. Determination of ﬂurbiprofen enantiomers(1) Chromatographic conditions
Mobile phase: acetonitrile–KH2PO4 (pH 4.5, 0.01M)
(70:30, v/v); ﬂow rate: 0.80 mL/min; detection wavelength:
250 nm; injection volume: 20 mL; column temperature:
room temperature.(2) Sample preparation and pre-column derivatization.
150 mL protein sample (pre-incubating at 37 1C for
10 min) was added to 10 mL centrifuge tube. Then the
internal standard ketoprofen and 100 mL of 1 M sulphu-
ric acid were added and vortically mixed. Afterward,
2 mL dichloromethane was added and vortically mixed
for 3 min, following by centrifugation for 10 min (3000g),
and then the lower organic layer was then transferred
into a 5 mL centrifuge tube, followed by vacuum drying.
Whereafter, 100 mL of 0.8% triethylamine-dichloro-
methane and 100 mL of 2% thionyl chloride-dichloro-
methane (freshly prepared) were added to the residue,
vortically mixing, and air-tightly reacting for 2 h at
30 1C. After vacuum drying 100 mL S-NEA dichloro-
methane (2.5 mg/mL, freshly prepared) was added to the
reaction solution. And then the reaction continued for
0.5 h at 30 1C. After vacuum drying the residue was
dissolved by the mobile phase.2.2.2. Determination of ketoprofen enantiomers(1) Chromatographic conditions
Mobile phase: acetonitrile–KH2PO4 (pH 4.5, 0.01 M)
(60:40, v/v); ﬂow rate: 0.80 mL/min; detection wave-
length: 250 nm; injection volume: 20 mL; column tem-
perature: room temperature.(2) Sample preparation and pre-column derivatization
The procedure of the sample preparation was the same
with ‘‘2.2.1 (2)’’ and the internal standard was ﬂurbiprofen.2.2.3. Determination of etodolac enantiomer(1) Chromatographic conditions
Mobile phase: methanol–KH2PO4 (pH 4.5, 0.01M)
(88:12, v/v); ﬂow rate: 0.80 mL/min; detection wave-
length: 278 nm; injection volume: 20 mL; Column tem-
perature: room temperature.(2) Sample preparation and pre-column derivatization
150 mL protein sample (pre-incubating at 37 1C for
10 min) was added to a 10 mL centrifuge tube. Then
100 mL of 1 M sulphuric acid was added and mixed by
vortexing. Afterward, 2 mL dichloromethane was added
and vortically mixed for 3 min, following by centrifuga-
tion for 10 min (3000g), and then the lower organic layer
was then transferred into a 5 mL centrifuge tube,
followed by vacuum drying. Thereafter, 50 mL HOBT
(2.5 mg/mL, including 1% pyridine), 100 mL EDC
(2.5 mg/mL) and 50 mL S-NEA (5 mg/mL) were added
to the residue (All the above solutions were freshly
prepared with dichloromethane), mixed by vortexing,
and air-tightly reacted for 2 h at 30 1C. After vacuum
drying the residue was dissolved by the mobile phase.2.2.4. HSA binding with the drug enantiomers(1) Nonspeciﬁc adsorption between drugs and the ultraﬁlter
Drugs were added to a 700 mL Sorenson phosphate
buffer (pre-incubating for 10 min at 37 1C). After vorti-
cally mixing, 500 mL phosphate buffer was taken into the
ultraﬁlter, centrifuging for 5 min at 37 1C (2000g), and
150 mL ultraﬁltrate was got. The ultraﬁltrate and the
phosphate buffer without ultraﬁltration were analyzed
Figur
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Adsorption rate of the ultrafilter :
P%¼ 1Aultrafiltrate=APBS
where Aultraﬁltrate is the peak area of the drug in the
ultraﬁltrate and APBS is the peak area of the drug in
phosphate buffer.(2) Chromatographic conditions for the determination of
ﬂurbiprofen and ketoprofen
Mobile phase: acetonitrile–KH2PO4 (pH 4.5, 0.01 M)
(60:40, v/v); ﬂow rate: 0.80 mL/min; detection wave-
length: 250 nm; injection volume: 20 mL; column tempera-
ture: room temperature.(3) Chromatographic conditions for the determination of
etodolac
Mobile phase: methanol–KH2PO4 (pH 4.5, 0.01 M)
(70:30, v/v); Flow rate: 0.80 mL/min; Detection wave-
length: 278 nm; Injection volume: 20 mL; Column tem-
perature: room temperature.(4) Experiments of binding with HSA
Appropriate amount HSA (40 mg/mL in the Sorenson
phosphate buffer) was added to make the ﬁnal concen-
tration of HSA 0.8% in the incubation medium. After
10 min pre-incubation at 37 1C, drugs were added and
vortically mixed, and then the incubation system was
placed in the constant temperature oscillation device,
incubating for 15 min. After the drugs bound completely
with plasma protein, 500 mL HSA was taken into the
ultraﬁlter, centrifuging for 5 min at 37 1C (10 000 rpm)e 1 HPLC chromatograms of ﬂurbiprofen enantiomers. (A) blank pla
rofen. Peaks: 1, S-ﬂurbiprofen; 2, R-ﬂurbiprofen; 3, R-ketoprofen (I.S
able 1 Recovery and precision of ﬂurbiprofen enantiomers (n¼5, m
Sample Spiked amount
(mg/mL)
Absolute recovery (%)
S R
HSA 1.0 88.1173.72 90.2573.7
5.0 91.4872.79 92.7572.1
50 88.4472.76 89.0172.8and 150 mL ultraﬁltrate was obtained. Afterward, the
disposal of the ultraﬁltrate was the same with ‘‘2.2.1 (2)’’.
Meanwhile, 150 mL HSA without ultraﬁltration was
parallelly operated according to the same method.3. Results and discussion
3.1. Determination of the three pairs of enantiomer
3.1.1. Determination of ﬂurbiprofen enantiomers
Under the optimized chromatographic conditions, the resolutions
between ﬂurbiprofen enantiomers and between ﬂurbiprofen and
the internal standard were good, while the retention time was
moderate, and there was no interference peak in all sample peak
position (Fig. 1). Therefore, this method has good speciﬁcity.
Under the above determination conditions, the method
exhibited excellent linear relationship with the concentration
of ﬂurbiprofen enantiomers in the range of 1.0–50 mg/mL. The
limits of detection (LOD) and quantitation (LOQ) were
303 ng/mL and 1.0 mg/mL, respectively. The regression equa-
tions are shown as follows: YS¼1.5897Cþ0.0751, r¼0.999;
YR¼1.6045Cþ0.0501, r¼0.999(1.0–50 mg/mL).
The results of recovery and precision of ﬂurbiprofen enantio-
mers are shown in Table 1.
3.1.2. Determination of ketoprofen enantiomers
Under the optimized chromatographic conditions, the resolutions
between ketoprofen enantiomers and between ketoprofen and thesma; (B) blank plasma spiked with racemic ﬂurbiprofen and
).
ean7SD).
Precision (%)
Intra-day Inter-day
S R S R
4 5.48 5.87 6.97 5.74
4 3.01 2.88 5.43 6.01
6 2.12 3.01 2.78 3.47
Analysis of chiral drug binding with HSA 187internal standard were good, while the retention time was
moderate, and there were no interference peaks in all sample
peak position (Fig. 2).
The signals responded linearly to the ketoprofen enantiomers’
concentration in the range of 1.0–50 mg/mL. The LOD and LOQ
were 303 and 1.0 mg/mL, respectively. The regression equations
are shown as follows: YS¼0.1267Cþ0.0186, r¼0.999;
YR¼0.1309Cþ0.0161, r¼0.999(1.0–50 mg/mL).
The results of recovery and precision of ketoprofen enan-
tiomers are shown in Table 2.Figure 2 HPLC chromatograms of ketoprofen enantiomers. (A) Bla
ﬂurbiprofen. Peaks: 1, S-ketoprofen; 2, R-ketoprofen; 3, S-ﬂurbiprofe
Table 2 Recovery and precision of ketoprofen enantiomers (n¼
Sample Spiked amount
(mg/mL)
Absolute recovery (%)
S R
HSA 1.0 91.4472.98 92.43
5.0 90.0173.45 91.91
50 88.4671.79 88.65
Figure 3 HPLC chromatograms of etodolac enantiomers. (A) Blank
S-etodolac; 2, R-etodolac.3.1.3. Determination results of etodolac enantiomers
The chromatograms of etodolac enantiomers are shown in
Fig. 3. The signals showed excellent linear relationship with
the concentration of etodolac enantiomers in the range of
1.0–50 mg/mL. The LOD and LOQ were 303 and 1.0 mg/mL,
respectively. The regression equations are shown as follows:
YS¼129.10Cþ115.24, r¼0.999; YR¼124.25Cþ128.54, r¼0.999
(1.0–50 mg/mL).
The recovery and precision results of etodolac enantiomers
are shown in Table 3.nk plasma; (B) blank plasma spiked with racemic ketoprofen and
n (I.S).
5, mean7SD).
Precision (%)
Intra-day Inter-day
S R S R
73.58 4.22 3.76 5.85 6.01
73.11 4.12 3.32 3.10 4.03
71.81 1.14 0.87 2.61 2.57
plasma; (B) blank plasma spiked with racemic etodolac. Peaks: 1,
Table 3 Recovery and precision of etodolac enantiomers (n¼5, mean7SD).
Sample Spiked amount
(mg/mL)
Absolute recovery (%) Precision (%)
Intra-day Inter-day
S R S R S R
HSA 1.0 91.9274.98 90.2174.81 8.08 6.87 7.92 6.84
5.0 89.4574.13 88.2773.89 5.21 4.89 5.43 5.02
50 90.7173.86 89.7573.11 3.89 4.07 2.88 3.15
Table 4 Nonspeciﬁc adsorption of chiral drugs with ultraﬁlter (n¼3).
Spiked amount
(mg/mL)
P (Flubiprofen)
(%)
P (Ketoprofen)
(%)
P (Etodolac)
(%)
1.0 2.78 3.77 4.21
5.0 1.72 3.86 2.15
50 1.41 2.95 2.01
P (%) 1.97 3.53 2.79
Figure 4 The binding of ﬂubiprofen enantiomers to HSA. (A) Unbound fraction of ﬂubiprofen enantiomers at various initial
concentrations. (B) Scatchard plots for the protein binding of ﬂubiprofen enantiomer.
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3.2.1. Nonspeciﬁc adsorption between drugs and the ultraﬁlter
The nonspeciﬁc adsorption of ﬂurbiprofen, ketoprofen and
etodolac at different concentrations with ultraﬁlter is shown in
Table 4. All the nonspeciﬁc adsorption rates of ﬂurbiprofen,
ketoprofen and etodolac are less than 5%, indicating that the
ultraﬁlter can be used for the determination of these drugs’
protein binding.
3.2.2. Drug enantiomers binding with HSA
As acidic drugs, ﬂurbiprofen, ketoprofen and etodolac mainly
bind with albumin in plasma. Being different from basic drugs,
acidic drugs seldom bind with other proteins such as acid
glycoprotein in plasma.
In human serum albumin, all the binding rate of ﬂurbiprofen,
ketoprofen and etodolac at the low concentrations is up to 95%.
Furthermore, the trend of the HSA binding rate with concentra-
tion is similar to that in plasma protein, indicating that albumin
afﬁnity site is the main binding sites. In albumin, ﬂurbiprofen
shows a weak stereoselectivity that the protein binding rate of
S-enantiomer is slightly higher than R-enantiomer (Fig. 4).However, the stereoselectivity of ketoprofen and etodolac in
HSA is the same with that in plasma (Figs. 5 and 6).
There are at least two types of binding sites at HSA of the
three drugs, viz. high afﬁnity sites and low afﬁnity sites. On the
basis of the literature reported [11–13], we used Eq. (1) for
the nonlinear least squares ﬁtting, and the binding constant is
shown in Table 5. Ketoprofen enantiomers did not show
stereoselectivity because the binding constants of S- and
R-enantiomer in the two types of binding sites were the same.
Etodolac has a strong chiral recognition (KS/KR¼6.06) in the
high afﬁnity sites. In the low concentration range, the signiﬁcant
differences of the protein binding rate of the S-enantiomer and
R-enantiomer are caused by the binding to the sites. When the
drug concentration is higher than 20 mg/mL, etodolac could
interact with the low afﬁnity sites and the stereoselectivity is
weakened. Generally speaking, such low afﬁnity and high
capacity sites are of poor stereoselectivity. As the drug enantio-
mers’ binding data in the experiments are measured in racemes,
for the high binding rate drugs, the possible competitive inhibition
between enantiomers can affect the accuracy of the binding
constant, thereby it could not actually reﬂect the interaction
between the single enantiomer and the protein [14]. Taking into
Figure 6 The binding of etodolac enantiomers to HSA. (A) Unbound fraction of etodolac enantiomers at various initial concentrations.
(B) Scatchard plots for the protein binding of etodolac enantiomer.
Table 5 Binding parameters of enantiomers of ﬂubipro-
fen, ketopreofen and etodolac in 1% HSA (n¼3).
Enantiomers Binding parameters
K1 ( 105) K2 ( 104) n1 n2
S-ﬂubiprofen 1.040 1.151 0.955 2.698
R-ﬂubiprofen 1.167 1.090 0.862 3.051
S-ketopreofen 0.933 0.811 1.003 2.861
R-ketopreofen 0.935 0.884 1.021 2.767
S-etodolac 5.301 2.341 0.875 1.983
R-etodolac 0.874 0.664 0.823 2.307
Figure 5 The binding of ketoprofen enantiomers to HSA. (A) Unbound fraction of ketoprofen enantiomers at various initial
concentrations. (B) Scatchard plots for the protein binding of ketoprofen enantiomer.
Analysis of chiral drug binding with HSA 189account that the three chiral drugs are commonly used as racemes
in clinical, the enantiomers–protein binding measured in the
racemes could better explain the actual disposition in in vivo
and thus still has important clinical signiﬁcance.
r¼ n1k1Cf
1þ k1Cf
þ n2k2Cf
1þ k2Cf
ð1Þ
4. Conclusion
In this paper, S-NEA was utilized as chiral derivatization reagent
and pre-column derivatization RP-HPLC method was established
for the separation of ketoprofen, ﬂurbiprofen and etodolacenantiomers. As acidic drugs, ketoprofen, ﬂurbiprofen and
etodolac enantiomers strongly interacted with serum albumin in
plasma and showed concentration-dependent. In serum albumin,
the protein binding of etodolac enantiomers showed signiﬁcant
stereoselectivity as the afﬁnity of S-enantiomer was stronger than
R-enantiomer, and the stereoselectivity ratio reached 6.06; ﬂurbi-
profen had only weak stereoselectivity in HSA, while ketoprofen
has no stereoselectivity at all. Scatchard curves showed that all
the three chiral drugs had two types of binding sites in HSA.Acknowledgements
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